Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of “Hold” by Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has earned a consensus rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $19.00.

ENTA has been the subject of several recent analyst reports. HC Wainwright reduced their price objective on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, JMP Securities reduced their price objective on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock opened at $13.14 on Thursday. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $22.13. The firm has a 50 day moving average price of $12.73 and a two-hundred day moving average price of $13.04. The firm has a market cap of $278.31 million, a price-to-earnings ratio of -2.11 and a beta of 0.60.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.21). Enanta Pharmaceuticals had a negative return on equity of 64.85% and a negative net margin of 180.76%. The firm had revenue of $17.05 million for the quarter, compared to the consensus estimate of $16.47 million. As a group, equities research analysts predict that Enanta Pharmaceuticals will post -5.95 EPS for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In related news, insider Tara Lynn Kieffer sold 7,266 shares of Enanta Pharmaceuticals stock in a transaction on Monday, June 17th. The shares were sold at an average price of $12.33, for a total value of $89,589.78. Following the completion of the sale, the insider now owns 32,341 shares of the company’s stock, valued at approximately $398,764.53. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 13.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,281 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth $118,000. Virtu Financial LLC bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth $191,000. Quest Partners LLC bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth $146,000. Finally, Diversified Trust Co bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth $159,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.